Merck reported Q3 2024 total sales of $16.7 billion, up 4% YoY (7% ex-exchange), driven by strong KEYTRUDA performance with sales growing 17% to $7.4 billion. WINREVAIR launch gained momentum with $149 million in sales, while Animal Health revenue rose 6% to $1.5 billion.GAAP EPS was $1.24 and non-GAAP EPS was $1.57, both including a net charge of $0.79 per share related to business development transactions with EyeBio, Curon Biopharmaceutical, and Daiichi Sankyo. The quarter saw lower GARDASIL sales due to reduced China demand, though growth remained strong in other regions.For full-year 2024, Merck narrowed its sales guidance to $63.6-64.1 billion and revised non-GAAP EPS to $7.72-7.77, reflecting a $0.24 per share impact from recent business development deals. The company achieved significant milestones in vaccine programs, including CDC recommendation for CAPVAXIVE in adults 50+ and positive clinical data for its RSV antibody candidate.

Merck reported Q3 2024 total sales of $16.7 billion, up 4% YoY (7% ex-exchange), driven by strong KEYTRUDA performance with sales growing 17% to $7.4 billion. WINREVAIR launch gained momentum with $149 million in sales, while Animal Health revenue rose 6% to $1.5 billion.GAAP EPS was $1.24 and non-GAAP EPS was $1.57, both including a net charge of $0.79 per share related to business development transactions with EyeBio, Curon Biopharmaceutical, and Daiichi Sankyo. The quarter saw lower GARDASIL sales due to reduced China demand, though growth remained strong in other regions.For full-year 2024, Merck narrowed its sales guidance to $63.6-64.1 billion and revised non-GAAP EPS to $7.72-7.77, reflecting a $0.24 per share impact from recent business development deals. The company achieved significant milestones in vaccine programs, including CDC recommendation for CAPVAXIVE in adults 50+ and positive clinical data for its RSV antibody candidate.